羟基喜树碱预防膀胱癌复发的临床研究(附154例报告)  

Clinical research of HCPT in the prevention of bladder carcinoma(Report of 154 cases)

作　　者：罗宏[1] 李元[1] 刘南[1] 周宏[1] 王传林[1] 朱葆捷[1] 

机构地区：[1]重庆市肿瘤医院泌尿外科,重庆400030

出　　处：《临床泌尿外科杂志》2005年第12期757-759,共3页Journal of Clinical Urology

摘　　要：目的:探讨预防膀胱癌术后复发更有效的方法.方法:术中系统采用羟基喜树碱液行肿瘤基底及切缘注射,浸泡膀胱和切口,术后膀胱灌注羟基喜树碱液治疗154例膀胱癌患者.结果:随访6个月～5年,平均49.6个月,总复发率29.2%,1年复发率18.8%,2年复发率6.4%,3年复发率1.3%,4年复发率1.9%,5年复发率0.6%.无一例发生切口种植转移及严重并发症.结论:术中术后应用羟基喜树碱预防膀胱癌术后复发安全有效.Objective：To investigate the more effective cure for the postoperative recurrence of bladder carcinoma. Methods： 154 patients were treated with tumor base injection, bladder incisional margin injection, bladder cavity and incision immersion intraoperatively, postoperation with the intravesical instillation of Hydroxycamptothecin （HCPT）. Results： The follow-up survey was for 6 months-5 years,49. 6 months averagely. The total recurrence rate is 29.2%, and recurrence rate of 1-5 years is showed apart as 18.8%, 6.4%, 1.3%, 1.9%, and 0.6%. Neither incision margin metastasis, nor serious complication was found. Conclusions： The HCPT is safe and effective for preventing the postoperative recurrence of bladder carcinoma.

关 键 词：膀胱肿瘤 药物治疗 羟基喜树碱 预防 

分 类 号：R747.14[医药卫生—神经病学与精神病学]